Mef2d is required for dermomyotome formation.

<p>(A) Embryos injected unilaterally with 400 pg of Mef2dF mRNA or 20 ng of moMef2d1 were fixed at stage 26 and submitted to staining with the specific muscle 12/101 antibody (red). (B) Expression of <i>Pax7</i> and <i>Pax3</i> mRNA at stage 17/18 (dorsal view or transverse sections at the trunk level). Co-staining of <i>Pax3</i> mRNA (purple) and differentiated muscle cells detected by 12/101 antibody (blue). Dotted lines indicate the position of the medial and lateral population of myogenic cells <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0052359#pone.0052359-Hinits1" target="_blank">[5]</a>. (C) Expression of <i>Pax3</i> mRNA on a transverse section at stage 22. (D) <i>Pax3</i> mRNA expression on lateral view (left) or on transverse section (right) at the tailbud stage after unilateral injection of Mef2dF or moMef2d1. Rescue experiments restored the phenotype of moMef2d1. Arrows indicate the sites of lateral ectopic expression of <i>Pax3</i>. (*) Injected side. Probes are in a framed box and indicated for each panel. Nc, notochord. For complete statistical data, see supporting information, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0052359#pone.0052359.s002" target="_blank">figure S2</a>.